Syed, M. http://orcid.org/0000-0002-7841-7792
Flechsig, P.
Liermann, J.
Windisch, P.
Staudinger, F.
Akbaba, S.
Koerber, S. A.
Freudlsperger, C.
Plinkert, P. K.
Debus, J.
Giesel, F.
Haberkorn, U.
Adeberg, S.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 23 November 2019
Accepted: 4 May 2020
First Online: 23 May 2020
Compliance with ethical standards
:
: Se.A and J.D. received grants from Accuray International SĂ rl outside the submitted work. Se.A. and J.D. received grants from Merck Serono GmbH outside the submitted work. J.D. received grants from The Clinical Research Institute GmbH (CRI), View Ray Inc., Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH and Nanobiotix A.A. outside the submitted work. The other authors declare no conflict of interest. Patent application for quinoline-based FAP targeting agents for imaging and therapy in nuclear medicine (C.K., T.L., U.H., F.L.G.). U.H. and F.G. also have shares of a consultancy group for iTheranostics.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Heidelberg University Hospital, Nr. S-421/2015) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All data were generated anonymously and according to ethical institutional policies.